Lilly begins a Phase 2 trial of eloralintide and tirzepatide in people with obesity and type 2 diabetes
CombinationP1Primary public evidenceTrial registry record
The registry lists a study start date of 20 September 2024 for NCT06603571, a Phase 2 trial of eloralintide (LY3841136) and tirzepatide, alone or in combination, in adults with obesity or overweight and type 2 diabetes. It lists 367 participants and a primary endpoint of percent change in body weight at week 48.
367
Participants, as recorded in the registry
Week 48
Time point of the primary endpoint, percent change in body weight
Background and context
What is compared
This Phase 2 study compares eloralintide and tirzepatide, alone or together, with placebo, double-blind, in adults with obesity or overweight and type 2 diabetes. It runs under the chronic weight management master protocol (NCT06143956). The primary endpoint is percent change in body weight from baseline to week 48, and participation lasts about 64 weeks.
Who took part
Adults aged 18 to 75 needed type 2 diabetes with an HbA1c from 7.0% to 10.5%, treated for at least three months with diet and exercise alone or with metformin, with or without an SGLT2 inhibitor. They also needed a BMI of at least 27 and a stable body weight. Exclusions include an eGFR below 45 and a history of pancreatitis. Sites are in the United States and Argentina.
Where it stands
The study is marked completed, with primary completion on 1 July 2026, but no results are posted. HbA1c, the share of participants losing 5% or 10% of body weight and drug levels are secondary measures, so they are registered plans, not findings.
Trial record: ClinicalTrials.gov NCT06603571, read on 2026-10-15. Registered plans can change.
P1Primary public evidenceTrial registry record.An official trial registration. A registration shows that a study exists; it does not show that the compound works.
